The WACC of Morepen Laboratories Ltd (MOREPENLAB.NS) is 17.2%.
| Range | Selected | |
| Cost of equity | 15.70% - 19.40% | 17.55% |
| Tax rate | 22.20% - 25.80% | 24.00% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 15.4% - 19.0% | 17.2% |
| Category | Low | High |
| Long-term bond rate | 6.9% | 7.4% |
| Equity market risk premium | 8.3% | 9.3% |
| Adjusted beta | 1.06 | 1.24 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 15.70% | 19.40% |
| Tax rate | 22.20% | 25.80% |
| Debt/Equity ratio | 0.03 | 0.03 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 15.4% | 19.0% |
| Selected WACC | 17.2% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for MOREPENLAB.NS:
cost_of_equity (17.55%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (1.06) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.